Comparative Efficacy and Safety of Vancomycin versus Teicoplanin: Systematic Review and Meta-Analysis
Open Access
- 1 October 2009
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 53 (10), 4069-4079
- https://doi.org/10.1128/aac.00341-09
Abstract
Vancomycin and teicoplanin are the glycopeptides currently in use for the treatment of infections caused by invasive beta-lactam-resistant gram-positive organisms. We conducted a systematic review and meta-analysis of randomized controlled trials that have compared vancomycin and teicoplanin administered systemically for the treatment of suspected or proven infections. A comprehensive search of trials without year, language, or publication status restrictions was performed. The primary outcome was all-cause mortality. Two reviewers independently extracted the data. Risk ratios (RRs) with 95% confidence intervals (CIs) were pooled by using the fixed-effect model (RRs of >1 favor vancomycin). Twenty-four trials were included. All-cause mortality was similar overall (RR, 0.95; 95% CI, 0.74 to 1.21), and there was no significant heterogeneity. In trials that used adequate allocation concealment, the results favored teicoplanin (RR, 0.82; 95% CI, 0.63 to 1.06), while in trials with unknown methods or inadequate concealment, the results favored vancomycin (RR, 3.61; 95% CI, 1.27 to 10.30). The latter trials might have recruited more severely ill patients. No other variable affected the RRs for mortality, including the assessment of glycopeptides administered empirically or for proven infections, neutropenia, the participant9s age, and drug dosing. There were no significant differences between teicoplanin and vancomycin with regard to clinical failure (RR, 0.92; 95% CI, 0.81 to 1.05), microbiological failure (RR, 1.24; 95% CI, 0.93 to 1.65), and other efficacy outcomes. Lower RRs (in favor of teicoplanin) for clinical failure were observed with a lower risk of bias and when treatment was initiated for infections caused by gram-positive organisms rather than empirically. Total adverse events (RR, 0.61; 95% CI, 0.50 to 0.74), nephrotoxicity (RR, 0.44; 95% CI, 0.32 to 0.61), and red man syndrome were significantly less frequent with teicoplanin. Teicoplanin is not inferior to vancomycin with regard to efficacy and is associated with a lower adverse event rate than vancomycin.Keywords
This publication has 62 references indexed in Scilit:
- Relationship between Vancomycin MIC and Failure among Patients with Methicillin-Resistant Staphylococcus aureus Bacteremia Treated with VancomycinAntimicrobial Agents and Chemotherapy, 2008
- Telavancin Versus Vancomycin for the Treatment of Complicated Skin and Skin‐Structure Infections Caused by Gram‐Positive OrganismsClinical Infectious Diseases, 2008
- Larger Vancomycin Doses (at Least Four Grams per Day) Are Associated with an Increased Incidence of NephrotoxicityAntimicrobial Agents and Chemotherapy, 2008
- Vancomycin In Vitro Bactericidal Activity and Its Relationship to Efficacy in Clearance of Methicillin-Resistant Staphylococcus aureus BacteremiaAntimicrobial Agents and Chemotherapy, 2007
- Prevalence and Characteristics of Heteroresistant Vancomycin-Intermediate Staphylococcus aureus Bacteremia in a Tertiary Care CenterJournal of Clinical Microbiology, 2007
- Telavancin Versus Standard Therapy for Treatment of Complicated Skin and Soft-Tissue Infections Due to Gram-Positive BacteriaClinical Infectious Diseases, 2005
- Cost Analysis of 2 Empiric Antibacterial Regimens Containing Glycopeptides for the Treatment of Febrile Neutropenia in Patients with Acute LeukaemiaPharmacoEconomics, 1999
- PP5. Teicoplanin or vancomycin in febrile neutropenic children with cancer: A randomized cost effectiveness studyEuropean Journal Of Cancer, 1997
- Comparative Study of Teicoplanin vs Vancomycin for the Treatment of Methicillin-Resistant Staphylococcus aureus BacteraemiaClinical Drug Investigation, 1996
- Teicoplanin: a well-tolerated and easily administered alternative to vancomycin for Gram-positive infections in intensive care patientsIntensive Care Medicine, 1994